Gastric cancer remains a major unmet clinical problem with over 1 million new cases
worldwide. It is the fourth most commonly occurring cancer in men and the seventh most …

Background & Aims Evidence suggests that a fraction of new gastric cancer cases may be
etiologically associated with Epstein-Barr virus (EBV), a known carcinogenic agent. We …

Gastric cancer (GC) is a severe malignancy, accounting for the third most common cancer
death worldwide. Despite the development of chemo-radiation therapy, there has not been …

Gastric cancer (GC) is an aggressive malignancy that is the third leading cause of cancer
mortality worldwide. Localized GC can be cured with surgery, but most patients present with …

Background Targeted sequencing using oncopanels requires comprehensive assessments
of accuracy and detection sensitivity to ensure analytical validity. By employing reference …

Cancer genome sequencing methods have now become essential for diagnostic purposes,
for devising treatment strategies, and for monitoring disease regression and progression …

Objective Tumor mutation burden (TMB) represents a useful biomarker for predicting
survival outcomes and immunotherapy response. Here, we aimed to conduct TMB-based …

Gastric cancer is an aggressive and heterogeneous malignancy that often varies in
presentation and disease among racial and ethnic groups. The Alaska Native (AN) people …

Recently, the combination of chemotherapy plus nivolumab (chemo-immunotherapy) has
become the standard of care for advanced-stage gastric cancer (GC) patients. However …

Reprimo-like (RPRML) is an uncharacterized member of the Reprimo gene family. Here, we
evaluated the role of RPRML and whether its regulation by DNA methylation is a potential …